Skip to main content

Table 2 Transition between biologic DMARDs during Corrona follow-up, 2002–2019

From: The sequence of disease-modifying anti-rheumatic drugs: pathways to and predictors of tocilizumab monotherapy

  First bDMARD DMARD use after baseline, as noted every 6 months on Corrona case report forms
0 months 6 months 12 months 18 months 24 months 30 months 36 months 42 months 48 months 54 months 60 months
(n = 7300) (n = 7250) (n = 6435) (n = 5769) (n =5153) (n = 4658) (n = 4175) (n = 3723) (n = 3359) (n = 3054) (n = 2764)
TCZ monotherapy 66 (0.90) 78 (1.08) 45 (0.70) 37 (0.64) 21 (0.41) 25 (0.54) 23 (0.55) 18 (0.48) 12 (0.36) 17 (0.56) 8 (0.29)
TCZ combination 117 (1.60) 128 (1.77) 117 (1.82) 122 (2.11) 123 (2.39) 109 (2.34) 97 (2.32) 67 (1.80) 59 (1.76) 47 (1.54) 45 (1.63)
TNFi, any 5889 (80.67) 4725 (65.17) 4000 (62.16) 3423 (59.33) 2980 (57.83) 2639 (56.66) 2284 (54.71) 1989 (53.42) 1764 (52.52) 1576 (51.6) 1402 (50.72)
nonTNF nonTCZ bDMARD 1228 (16.82) 1137 (15.68) 1027 (15.96) 938 (16.26) 852 (16.53) 802 (17.22) 749 (17.94) 707 (18.99) 671 (19.98) 609 (19.94) 575 (20.8)
csDMARD combination 946 (13.05) 996 (15.48) 998 (17.3) 946 (18.36) 880 (18.89) 812 (19.45) 761 (20.44) 690 (20.54) 657 (21.51) 597 (21.6)
No DMARD 236 (3.26) 250 (3.89) 251 (4.35) 231 (4.48) 203 (4.36) 210 (5.03) 181 (4.86) 163 (4.85) 148 (4.85) 137 (4.96)
  1. TCZ tocilizumab; TNFi TNF inhibitors; nonTNF nonTCZ bDMARD, includes all JAK inhibitors, abatacept, and rituximab; DMARD disease-modifying anti-rheumatic drugs; bDMARDs biologic DMARDs; csDMARDs conventional synthetic DMARDs